Oxidative and nitrosative stress and histone deacetylase-2 activity in exacerbations of COPD

Chest

Volumn 149, Issue 1, 2016, Pages 62-73

  Footitt, Joseph ^a   Mallia, Patrick ^a   Durham, Andrew L ^b   Eugene Ho, W ^b   Trujillo Torralbo, Maria Belen ^c   Telcian, Aurica G ^c   Rosario, Ajerico Del ^d   Chang, Cheng ^e   Peh, Hong Yong ^a   Kebadze, Tatiana ^b   Aniscenko, Julia ^c   Stanciu, Luminita ^e   Essilfie Quaye, Sarah ^d   Ito, Kazuhiro ^b   Barnes, Peter J ^a   Elkin, Sarah L ^c   Kon, Onn M ^e   Fred Wong, W S ^a   Adcock, Ian M ^b   Johnston, Sebastian L ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b Mss Trujillo Torralbo and Aniscenko   (United Kingdom)

^c IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

COPD; Host defense; Infection; Viral disease

Indexed keywords

ACETYLCYSTEINE; GELATINASE B; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE 2; INTERLEUKIN 1BETA; INTERLEUKIN 8; LEUKOCYTE ELASTASE; TUMOR NECROSIS FACTOR ALPHA; AUTACOID;

ADULT; ARTICLE; CELL DAMAGE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ALVEOLUS MACROPHAGE; MALE; MIDDLE AGED; MONOCYTE; NITROSATIVE STRESS; NITROSYLATION; OXIDATIVE STRESS; PRIORITY JOURNAL; RESPIRATORY TRACT INFLAMMATION; RHINOVIRUS INFECTION; SMOKING; SPUTUM ANALYSIS; VIRUS LOAD; CASE CONTROL STUDY; COMPLICATION; DISEASE COURSE; METABOLISM; NITROSATION; PHYSIOLOGY; PICORNAVIRUS INFECTION; RHINOVIRUS; SPUTUM;

CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; HISTONE DEACETYLASE 2; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; NITROSATION; OXIDATIVE STRESS; PICORNAVIRIDAE INFECTIONS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RHINOVIRUS; SPUTUM; VIRAL LOAD;

EID: 84954152909     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.14-2637     Document Type: Article

References (45)

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11): e442
2. Vestbo J, Hurd SS, Agust AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347-365
3. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006;173(10):1114-1121
4. Singanayagam A, Joshi PV, Mallia P, Johnston SL. Viruses exacerbating chronic pulmonary disease: the role of immune modulation. BMC Med. 2012;10:27
5. Walters JA, Gibson PG, Wood-Baker R, Hannay M, Walters EH. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2009;(1): CD001288
6. Vollenweider DJ, Jarrett H, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;(12):CD010257
7. Fischer BM, Pavlisko E, Voynow JA. Pathogenic triad in COPD: oxidative stress, protease-Antiprotease imbalance, and inflammation. Int J Chron Obstruct Pulmon Dis. 2011;6:413-421
8. Ito K, Ito M, Elliott WM, et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med. 2005;352(19):1967-1976
9. Ricciardolo FL, Caramori G, Ito K, et al. Nitrosative stress in the bronchial mucosa of severe chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2005;116(5):1028-1035
10. Chiba T, Chihara J, Furue M. Role of the arylhydrocarbon receptor (AhR) in the pathology of asthma and COPD. J Allergy (Cairo). 2012;2012:372-384
11. Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2013;131(3):636-645
12. Osoata GO, Yamamura S, Ito M, et al. Nitration of distinct tyrosine residues causes inactivation of histone deacetylase 2. Biochem Biophys Res Commun. 2009;384(3):366-371
13. To Y, Ito K, Kizawa Y, et al. Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182(7):897-904
14. Mallia P, Message SD, Contoli M, et al. Lymphocyte subsets in experimental rhinovirus infection in chronic obstructive pulmonary disease. Respir Med. 2014;108(1):78-85
15. Mallia P, Message SD, Gielen V, et al. Experimental rhinovirus infection as a human model of chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med. 2011;183(6): 734-742
16. Mallia P, Message SD, Kebadze T, Parker HL, Kon OM, Johnston SL. An experimental model of rhinovirus induced chronic obstructive pulmonary disease exacerbations: a pilot study. Respir Res. 2006;7:116
17. Celli BR, MacNee W; ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932-946
18. Koksel O, Cinel I, Tamer L, et al. N-Acetylcysteine inhibits peroxynitritemediated damage in oleic acid-induced lung injury. Pulm Pharmacol Ther. 2004;17(5):263-270
19. Kanazawa H, Shiraishi S, Okamoto T, Hirata K, Yoshikawa J. Inhibition of bronchoprotective effects of beta2-Adrenoceptor agonists by peroxynitrite in guinea pig airways. Am J Respir Crit Care Med. 1999;159(4 pt 1):1272-1276
20. Kondo H, Takahashi M, Niki E. Peroxynitrite-induced hemolysis of human erythrocytes and its inhibition by antioxidants. FEBS Lett. 1997;413(2): 236-238
21. Tsoumakidou M, Tzanakis N, Chrysofakis G, Siafakas NM. Nitrosative stress, heme oxygenase-1 expression and airway inflammation during severe exacerbations of COPD. Chest. 2005;127(6):1911-1918
22. Drost EM, Skwarski KM, Sauleda J, et al. Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax. 2005;60(4):293-300
23. Biernacki WA, Kharitonov SA, Barnes PJ. Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD. Thorax. 2003;58(4):294-298
24. Dekhuijzen PN, Aben KK, Dekker I, et al. Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1996; 154(3 pt 1):813-816
25. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55(2): 114-120
26. Roland M, Bhowmik A, Sapsford RJ, et al. Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease. Thorax. 2001;56(1): 30-35
27. Koutsokera A, Kiropoulos TS, Nikoulis DJ, et al. Clinical, functional and biochemical changes during recovery from COPD exacerbations. Respir Med. 2009;103(6):919-926
28. Kersul AL, Iglesias A, Ros A, et al. Molecular mechanisms of inflammation during exacerbations of chronic obstructive pulmonary disease. Arch Bronconeumol. 2011;47(4):176-183
29. Cosio BG, Iglesias A, Rios A, et al. Lowdose theophylline enhances the antiinflammatory effects of steroids during exacerbations of COPD. Thorax. 2009;64(5):424-429
30. Mallia P, Footitt J, Sotero R, et al. Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(11):1117-1124
31. Mallia P, Message SD, Contoli M, et al. Neutrophil adhesion molecules in experimental rhinovirus infection in COPD. Respir Res. 2013;14:72
32. DonaldsonGC, SeemungalTA, BhowmikA, Wedzicha JA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847-852
33. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178(4):332-338
34. Kanner RE, Anthonisen NR, Connett JE; Lung Health Study Research Group. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med. 2001;164(3):358-364
35. de Boer WI, Yao H, Rahman I. Future therapeutic treatment of COPD: struggle between oxidants and cytokines. Int J Chron Obstruct Pulmon Dis. 2007;2(3): 205-228
36. Sugiura H, Liu X, Kobayashi T, et al. Reactive nitrogen species augment fibroblast-mediated collagen gel contraction, mediator production, and chemotaxis. Am J Respir Cell Mol Biol. 2006;34(5):592-599
37. ODonnell R, Breen D, Wilson S, Djukanovic R. Inflammatory cells in the airways in COPD. Thorax. 2006;61(5): 448-454
38. Demedts IK, Brusselle GG, Bracke KR, Vermaelen KY, Pauwels RA. Matrix metalloproteinases in asthma and COPD. Curr Opin Pharmacol. 2005;5(3):257-263
39. Ito K, Hanazawa T, Tomita K, Barnes PJ, Adcock IM. Oxidative stress reduces histone deacetylase 2 activity and enhances IL-8 gene expression: role of tyrosine nitration. Biochem Biophys Res Commun. 2004;315(1):240-245
40. Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2012;186(1):48-55
41. Rennard SI, Fogarty C, Kelsen S, et al; COPD Investigators. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(9):926-934
42. Mahler DA, Huang S, Tabrizi M, Bell GM. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. Chest. 2004;126(3): 926-934
43. Aaron SD, Vandemheen KL, Maltais F, et al. TNFa antagonists for acute exacerbations of COPD: a randomised double-blind controlled trial. Thorax. 2013;68(2):142-148
44. Vogelmeier C, Aquino TO, OBrien CD, Perrett J, Gunawardena KA. A randomised, placebo-controlled, dosefinding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium. COPD. 2012;9(2):111-120
45. Chang HM, Paulson M, Holko M, et al. Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc Natl Acad Sci U S A. 2004;101(26):9578-9583